• Discover Astex
    • Our Mission & Values
    • Our Leadership Team
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
      • Partnered Products and Programs
        • Kisqali® (ribociclib) CDK4/6 inhibitor (Oncology)
        • Balversa® (erdafitinib) FGFr inhibitor (Oncology)
        • Truqap® PKB/Akt Inhibitor (Oncology)
        • KRAS Oncogene (Oncology)
        • Beroterkib (ASTX029) Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
        • ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
        • SHP2 (Oncology)
        • P53 tumour suppressor protein (Oncology)
      • Proprietary Products and Programs
        • Tolinapant (ASTX660) Dual IAP Antagonist (T-cell Lymphomas)
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
You are here: Home1 / AT7519 – CDK inhibitor2 / 20113 / 2011 EORTC: Phase 1 Study of AT7519M Short Infusion Twice Weekly

2011 EORTC: Phase 1 Study of AT7519M Short Infusion Twice Weekly

25 November 2011/in 2011, AT7519 – CDK inhibitor

2011 EORTC: Phase 1 Study of AT7519M Short Infusion Twice Weekly

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2011-11-25 13:59:542016-11-25 14:05:412011 EORTC: Phase 1 Study of AT7519M Short Infusion Twice Weekly

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal
  • LinkedIn

Member of the Otsuka Group

A selection of photos on this website
is courtesy of Valerio Berdini

Link to: Astex Pharmaceuticals Reports 2011 Third Quarter Financial Results Link to: Astex Pharmaceuticals Reports 2011 Third Quarter Financial Results Astex Pharmaceuticals Reports 2011 Third Quarter Financial Results Link to: 2011 EORTC: AT13387 Anti-Tumor Activity in imatinib-sensitive and -resistant GIST Models Link to: 2011 EORTC: AT13387 Anti-Tumor Activity in imatinib-sensitive and -resistant GIST Models 2011 EORTC: AT13387 Anti-Tumor Activity in imatinib-sensitive and -resistant...
Scroll to top Scroll to top Scroll to top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok